HEALTH AND SAFETY

» Drug, Devices, and Supplements

» Physician Accountability

» Consumer Product Safety

» Worker Safety

» Health Care Delivery

» Auto and Truck Safety

» Global Access to Medicines

» Infant Formula Marketing

 

More information on nevirapine (Viramune)

Letter in the Lancet Detailing Unethical Nevirapine (Viramune) Trials

This letter, by Health Research Group Deputy Director Peter Lurie, M.D., MPH and Director Sidney Wolfe, M.D., appeared in the Lancet on November 20, 1999.

Sir--Although Laura Guay and colleagues' (Sept 4, p 795) [1] study on the effectiveness of nevirapine in reducing perinatal HIV-1 transmission offers hope for reducing the enormous global toll of HIV-1 infection, their work remains deeply unethical. For 14 months after an antepartum and intrapartum regimen of zidovudine was shown in Thailand to reduce HIV-1 transmission by 51%, [2] Guay and colleagues continued to enrol participants without providing antepartum antiretroviral drugs. This practice continued for 6 months after WHO had recommended antepartum and intrapartum zidovudine therapy in less developed countries "where adequate infrastructure is in place", [3] a condition certainly met in this study. Because the mothers were enrolled as early as 32 weeks' gestation, there was ample opportunity to provide this life-saving medication.

[1] Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354: 795-802.

[2] CDC. Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission: Thailand 1996-1998. MMWR Morb Mortal Wkly Rep 1998; 47: 151-54. [PubMed]

[3] WHO. Recommendations on the safe and effective use of short-course ZDV for prevention of mother-to-child transmission of HIV. Wkly Epidemiol Rec 1998; 73: 313-20. [PubMed]

Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.